Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PellePharm's Topical Patidegib Nears Phase III For Gorlin Syndrome

Executive Summary

Gel formulations of the hedgehog signalling inhibitor patidegib may be the long sought well-tolerated and effective therapy for basal cell carcinoma and the rare disease, Gorlin syndrome.

You may also be interested in...



Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib

Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.

The Next Roivant Or Fortress? BridgeBio Raises $135m To Spin Out New Companies

BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel